Tonix Pharmaceuticals Holding Corp. (Tonix), a biopharmaceutical company, announced on March 21, 2024, the presentation of a poster at the American Chemistry Society (ACS) Spring 2024 Meeting, which took place from March 17 to March 21, 2024. The poster, titled 'Oxytocin Analogs with Enhanced Craniofacial Antinociceptive Effects in Low Magnesium Formulations,' detailed the discovery of novel oxytocin analogues that may serve as treatments for craniofacial pain, excessive eating disorders including Prader Willi Syndrome, and certain endocrinological conditions. The company highlighted that these analogues have improved binding to magnesium, potentially eliminating the need for magnesium augmentation in their activity, unlike intranasal oxytocin. Tonix also reported ongoing Phase 2 studies of TNX-1900 for conditions such as pediatric obesity, binge eating disorder, bone health in autism, and social anxiety disorder. Additionally, TNX-2900 is being developed for Prader-Willi Syndrome and has received orphan drug designation from the FDA. The company aims to submit a New Drug Application (NDA) for another candidate, Tonmya, for the management of fibromyalgia in the second half of 2024.

Tonix Pharmaceuticals Holding Corp. (Tonix), a biopharmaceutical company, announced on March 21, 2024, the presentation of a poster at the American Chemistry Society (ACS) Spring 2024 Meeting, which took place from March 17 to March 21, 2024. The poster, titled 'Oxytocin Analogs with Enhanced Craniofacial Antinociceptive Effects in Low Magnesium Formulations,' detailed the discovery of novel oxytocin analogues that may serve as treatments for craniofacial pain, excessive eating disorders including Prader Willi Syndrome, and certain endocrinological conditions. The company highlighted that these analogues have improved binding to magnesium, potentially eliminating the need for magnesium augmentation in their activity, unlike intranasal oxytocin. Tonix also reported ongoing Phase 2 studies of TNX-1900 for conditions such as pediatric obesity, binge eating disorder, bone health in autism, and social anxiety disorder. Additionally, TNX-2900 is being developed for Prader-Willi Syndrome and has received orphan drug designation from the FDA. The company aims to submit a New Drug Application (NDA) for another candidate, Tonmya, for the management of fibromyalgia in the second half of 2024.